Economic evaluation of Tacrolimus and Hydrocortisone in acute flare of atopic dermatitis
Publication date: 2021
Content type: article
ABSTRACT Introduction: Atopic dermatitis (AD) is a chronic, remitting-relapsing, and inflammatory dermatosis. It occurs in patients of all ages, with a peak in children and young adults. Immunomodulator treatment improves the quality of life by reducing the intensity and frequency of symptomatic periods, number of physician visits, and cost of the treatment for patients and the health system. Methodology: A cost-effectiveness analysis, comparing tacrolimus and hydrocortisone butyrate 1% to treat an acute flare of moderate to severe AD in Colombia for patients aged two years or older. A decision tree model was designed in this analysis, and we used a health system perspective and evaluated only direct costs, during 2019. Results: The treatment of a symptomatic exacerbation episode of moderate to severe AD is cost-effective with tacrolimus compared to hydrocortisone. Discussion: tacrolimus is dominant and can be cost-saving because its use reduces complications and adverse events that increase treatment costs. Conclusion: The use of tacrolimus will benefit both patients and the health care system.
Files in this item
- Tacrolimus-project-14-junio-20 ...